Ascendis Pharma shares are trading higher after the company announced that data from the Phase 2 PaTH study of its TransCon PTH showed sustained efficacy and safety in participants with hypoparathyroidism.

Benzinga Newsdesk www.benzinga.com Positive 95.2%

Neg 0% Neu 0% Pos 95.2%

Comments

No comments yet. Be the first!